country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-105249

Copy Link Print Information

RDEA 806

RDEA 806 is an orally effective non-nucleoside reverse transcriptase (NNRT) inhibitor that exhibits potent in vitro inhibitory activity against wild-type HIV-1 (EC₅₀ = 1.7 ng/mL) and NNRTI-resistant HIV-1. RDEA 806 rapidly reduces HIV-1 RNA viral load in vivo. RDEA 806 has a favorable biosafety profile. RDEA 806 can be used for research related to HIV-1 infection.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 878670-61-2
Formel: C₂₄H₁₈BrClN₄O₃S
Molecular Weight:557.85

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (281 KB)

RDEA 806 Chemical Structure

CAS. Nr.: 878670-61-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- Clinical Trial
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle HIV Isoform-spezifische Produkte anzeigen :

In Vitro

RDEA 806 exhibits potent in vitro activity against wild-type HIV-1 with an EC₅₀ of 1.7 ng/mL and retains activity against common NNRTI-resistant mutants^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Research Protocol for Infectious Diseases

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 878670-61-2
Molecular Weight 557.85
Formel C₂₄H₁₈BrClN₄O₃S
SMILES

ClC(C=C(C(O)=O)C=C1)=C1NC(CSC2=NN=C(Br)N2C3=CC=C(C4CC4)C5=C3C=CC=C5)=O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Moyle G, et al. Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects. Antimicrobial agents and chemotherapy. 2010 Aug;54(8):3170-8.

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen